ImmunityBio, Inc. IBRX Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction?
- ImmunityBio, Inc. (IBRX) reported debt issuance costs incurred during noncash or partial noncash transaction of $54K in Q1 2026.